GE HealthCare buys SOFIE Biosciences for $945 M to establish 'Final Mile' footprint for PET Radiopharmaceutical Supply in US
GE HealthCare agreed to buy SOFIE Biosciences for $945 million in cash, expanding its US PET radiopharmaceutical supply network. The deal, expected to close in H1 2027, adds 15 CMO sites and 21 cyclotrons, enhancing GE HealthCare's theranostics capabilities. SOFIE will join GE HealthCare's PDx segment.
How this was made

The 30-second read
Why it matters
The deal adds a final‑mile capability for PET radiopharmaceuticals, a high‑growth niche in precision medicine.
Market read
The acquisition could enhance GE's competitive position in theranostics while requiring significant cash, likely influencing its stock price in the short term.
What to watch
Regulatory approval risk for the integration of a CMO and potential competition from other radiopharma providers.
Background
GE HealthCare is a major US‑listed medical‑technology company expanding its diagnostics portfolio.
Ticker impact
GE HealthCare announced a definitive agreement to acquire SOFIE Biosciences for $945 million in cash.
likely modest pressure as investors price in the $945M cash payment and integration risk
Large cash deal for a private CMO; market typically reacts with slight downside on the acquirer.
Market effects
Expands GE HealthCare's footprint in the growing PET radiopharmaceutical and theranostics market.
Strengthens US domestic supply chain for PET agents, potentially benefiting related imaging equipment makers.
Positions GE as a more integrated player in global precision‑medicine supply chains.
Counterpoint
The cash outlay may strain GE's balance sheet and dilute earnings, outweighing strategic benefits.
Key entities
- CompanyGE HealthCare
US‑listed medical‑technology firm (ticker GE).
- CompanySOFIE Biosciences
US‑based contract manufacturing organization for PET radiopharmaceuticals.



